KUALA LUMPUR, Aug 21 (Bernama) -- Toshiba Electronic Devices & Storage Corporation (Toshiba) has launched the "TLX9161T", an automotive photorelay engineered for electric vehicle (EV) battery systems, with volume shipments having begun.
According to Toshiba in a statement, with a minimum output withstand voltage of 1500 volts (V), the new product meets the stringent requirements for high-voltage EV batteries.
The photorelay, built in a compact SO12L-T package, offers a 25 per cent smaller mounting area than its predecessor, the TLX9160T SO16L-T package. The reduced footprint contributes to more compact and cost-efficient battery management systems (BMS), which are crucial for optimising EV battery performance and safety.
Photorelays like this are critical in BMS applications, where they manage isolation between the vehicle body and battery, a key safety feature in high-voltage environments.
By miniaturising the internal MOSFET chip, Toshiba has maintained compatibility with existing circuit board designs while enhancing performance.
The new photorelay uses a resin with a Comparative Tracking Index (CTI) exceeding 600, which is classified under Material Group I of the IEC 60664-1 international standard. It also ensures over five millimetres of creepage distance, aligning with global safety standards for 1000V operations.
Toshiba will continue to expand its lineup of automotive photorelay products and provide solutions that address the challenges in popularising EVs, aiming to contribute to the realisation of a carbon-neutral society.
-- BERNAMA
Friday, August 22, 2025
TOSHIBA UNVEILS COMPACT HIGH-VOLTAGE PHOTORELAY FOR EV BATTERY SYSTEMS
Thursday, August 21, 2025
MELTWATER TAPS DOW JONES TO DELIVER PREMIUM NEWS TO PR, MARKETING PROFESSIONALS
KUALA LUMPUR, Aug 21 (Bernama) -- Meltwater has announced a strategic partnership with Dow Jones, giving its global user base access to premium, subscriber-only content from top-tier publications, including The Wall Street Journal, Barron’s, MarketWatch, The Globe and Mail.
The agreement enhances Meltwater’s media, social and consumer intelligence platform, enabling public relations (PR), marketing, and communications professionals to track high-value news on their companies, competitors, and industries with more profound insight and broader reach.
Meltwater chief executive officer, John Box said the move underscores the company’s commitment to delivering unmatched data coverage across news, social, and broadcast platforms.
“With this new agreement with Dow Jones, Meltwater continues in our mission to unlock the world’s online data and provide more content than anyone else in the market,” he said in a statement.
Meanwhile, Dow Jones general manager of Corporate Partnerships, William Ashworth said the collaboration combines the strengths of both companies to deliver world-class news and analysis.
Meltwater users will now be able to integrate Dow Jones’ high-quality content with data from other top-tier sources like Bloomberg Media, Torstar, and The Washington Post, supporting more informed, data-driven strategies.
The partnership is expected to bolster decision-making across sectors by putting trusted journalism at the fingertips of the professionals who shape public narratives.
-- BERNAMA
Tuesday, August 19, 2025
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
- Data on Alcon’s products across cataract, refractive, diagnostics and ocular health will be featured in presentations during the meeting
- Prospective analyses and studies demonstrate sustained performance of Vivity including in patients with common mild comorbidities
- Alcon’s Symposia on new generation phaco and vitrectomy system will discuss new data on anterior chamber stability during cataract surgery performed at more physiologic IOP
AHMEDABAD, India, Aug 19 (Bernama-BUSINESS WIRE) -- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations.
Massimo Cerrone, Vice President, Surgical for Alcon Asia Pacific, said, “APACRS brings together leading experts and their insights from across the region, creating an ideal environment to engage in critical topics such as the evolving needs of cataract care in the ageing population. Through a dynamic agenda, surgeons can explore Alcon’s latest innovations and their value through clinical evidence, real-world insights, and peer experience across Asia-Pacific.”
Key data being presented at this year’s event
- Alcon’s Vivity® is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, ‘To Evaluate The Visual Outcomes and Patient Satisfaction After Bilateral Vivity® IOL Implantation in Patients with Mild Irregular Astigmatism.’ Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. This will be shared as an e-poster.
- On the cataract equipment side, Dr. Shail Vasavada of Raghudeep Eye Hospital, will present a prospective, randomized, single masked, single-center study titled, ‘Retinal Perfusion During Cataract Surgery With Varying Intraocular Pressure in Comorbid Eyes.’ Data underlines the benefits of performing cataract surgery at more physiologic IOP in patients with diabetic retinopathy. (Friday, 22 August 2025, 15:20pm-15:25pm, at FP3-15, Seminar Hall 2, MMCEC)
Amar Vyas, Country Head, Alcon India said, “We are excited that India is hosting APACRS for the second time. The event is an ideal platform to showcase our breakthrough technologies like the Advanced Technology IOL portfolio and UNITY VCS/CS, and foster meaningful exchange amongst ECPs. As cataract procedures rise, it’s critical that advanced technologies are both clinically proven across diverse patient populations and accessible to those who need them. We remain committed to empowering surgeons with science-backed solutions that elevate surgical precision and patient outcomes.”
During the meeting, Alcon will host four symposia; interested participants can learn more and register at https://events.myalcon.com/professional/events/apacrs;
During the meeting, Alcon will host four symposia; interested participants can learn more and register at https://events.myalcon.com/professional/events/apacrs;
- Alcon UNITY® VCS Launch Symposium - Ready to explore the future of Surgical Innovation? Experience Superior Efficiency - Unity® VCS, held exclusively for India on Thursday, 21 August 2025, 12:45pm to 13:40pm IST at Seminar Hall 2, Ground Floor. This session will mark the official introduction of UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), Alcon’s next-generation Phaco/Vit platform, to the Indian market.
- Alcon IOL Symposium - Stay Ahead with the Clareon® Collection on Friday, 22 August 2025,12:30pm to 13:25pm IST at Convention Hall 2, Ground Floor. This session will cover the Clareon Collection as a comprehensive IOL portfolio, discuss optical differentiation and performance of newer EDOF IOLs, and highlight the role of digital image guidance in toric correction.
- Alcon Surgical Video Symposium - Experience Extraordinary Phaco & VR Surgery with the NEW UNITY® VCS by Alcon on Saturday, 23 August 2025, 12:00pm to 12:55pm IST at Convention Hall 2, Ground Floor. Through live discussion and videos, leading surgeons will showcase their experience with UNITY VCS in cataract and vitreoretinal procedures.
- Alcon Global Medical Affairs symposium - Vivity IOL, A True EDOF IOL with Proven Real-World Performance on Saturday, 23 August 2025, 13:00pm to 14:00pm IST at Seminar Hall 2, Ground Floor. The session, moderated by Dr. Vaishali Vasavada, will review meaningful real-world evidence supporting the use of Vivity IOL in special populations. To reserve your seat, visit https://cvent.me/9vgqzy.
For information on Alcon’s presence at APACRS 2025, including the symposia and exhibition taking place at booth #A1, please visit the company’s event page. The site will be updated following the event with on-demand content, such as archives of the symposia. Join the conversation on social platforms with the hashtag #APACRS2025 #Alcon.
About the AcrySof IQ Vivity IOL
The Wavefront Shaping AcrySof® IQ Vivity Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof IQ Vivity IOL) is a UV-absorbing and blue light-filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances.1
About UNITY VCS and UNITY CS
The UNITY VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery.2
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
The content of this press release is intended for use by healthcare professionals only, including Registered Medical Practitioners, hospitals, or laboratories, and its use in any publication is subject to applicable local laws and regulations.
References
- Acrysof IQ Vivity Extended Vision IOL Global Directions for Use [REF-22568]
- UNITY VCS and CS User Manual 2024 [REF-27652]
Connect with us on:
View source version on businesswire.com: https://www.businesswire.com/news/home/20250818783931/en/
Contact
Media Relations
MinSeo Kim
MinSeo.Kim@alcon.com
+821063849533
Pooja Behuria
Pooja.behuria@edelman.com
9884646793
Source : Alcon Inc. Corporate
Friday, August 15, 2025
INSERTING and REPLACING SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results
IRVINE, Calif., Aug 15 (Bernama-BUSINESS WIRE) --
Insert after the second paragraph, 9th bullet: First Half 2025 Highlights.
The updated release reads:
SBC MEDICAL GROUP HOLDINGS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025).
Second Quarter 2025 Highlights
Insert after the second paragraph, 9th bullet: First Half 2025 Highlights.
The updated release reads:
SBC MEDICAL GROUP HOLDINGS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025).
Second Quarter 2025 Highlights
- Total revenues were $43 million, representing an 18% year-over-year decrease.
- Income from operations was $15 million, representing a 47% year-over-year decrease.
- Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease.
- Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.02 for the three months ended June 30, 2025, compared to $0.20 in the same period of 2024.
- EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $15 million, representing a 46% year-over-year decrease. EBITDA margin1 was 35% for the second quarter of 2025, compared to 53% for second quarter of 2024.
- Return on equity, which is defined as net income attributable to the Company divided by the average of shareholder’s equity as of June 30, 2025, was 4% representing a year-over-year decrease of 44 percentage points.
- Number of Franchise Locations2 was 259 as of June 30, 2025, representing an increase of 36 locations from June 30, 2024.
- Number of customers3 in the last twelve months ended June 30, 2025, was 6.31 million, representing a 14% year-over-year increase.
- Repeat rate for customers4 who visited franchisee’s clinics twice or more was 72%.
First Half 2025 Highlights
- Total revenues were $91 million, representing a 16% year-over-year decrease.
- Income from operations was $39 million, representing a 25% year-over-year decrease.
- Net Income attributable to SBC Medical Group was $24 million, representing a 36% year-over-year decrease.
- Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.23 for the six months ended June 30, 2025, compared to $0.40 in the same period of 2024.
- EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $40 million, representing a 25% year-over-year decrease. EBITDA margin1 was 44% for the first half of 2025, compared to 50% for first half of 2024.
Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, “ As anticipated and signaled in our prior guidance, Q2 2025 reflected strategic shifts aimed to position SBC Medical for long-term competitiveness and scalability. Total revenue declined 18% year-over-year to $43 million, primarily due to the completed discontinuation of our staffing business, targeted divestitures to streamline our operations, and revision of fee structure. We are executing our strategic plan with precision, as evidenced by our network of 259 Franchise Locations as of June 30, 2025 and 6.31 million visits over the last twelve months, demonstrating a scale that is unmatched in Japan. Our high repeat rate underscores the strength of our Shonan Beauty Clinic brand. Japan’s consumer discretionary market faces challenges, including restrained growth due to trade restrictions and cautious consumer spending. Despite these headwinds, we are successfully advancing key initiatives, including the acquisition of MB career lounge to enhance our management support services and the joining of JUN CLINIC to our network, which boasts a high average spend per customer. Looking ahead, we remain confident in our strategic roadmap, focused on optimizing our franchise model, capturing growth opportunities, transitioning to higher-margin models, and delivering lasting value to our shareholders.”
Second Quarter 2025 Financial Results
Total revenues were $43 million, a decrease of 18% year-over-year, primarily due to a revised fee structure for franchising services implemented starting from April 2025, the discontinuation staffing services business, and divestiture of SNA and Kijimadaira, partially offset by growth in procurement, rental services, and other revenue streams.
Net income attributable to SBC Medical Group for the three months ended June 30, 2025 was $2.5 million, compared to $18.5 million in the same period of 2024. The decrease was largely attributed to unfavorable changes in other income and expenses, primarily due to higher foreign exchange losses.
EBITDA1 was $15 million, a decrease of 46% year-over-year, primarily due to lower revenue following the termination of the staffing services business, the deconsolidation of SNA and Kijimadaira, and revision of fee structure.
Conference Call
The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live.
Please register in advance of the conference using the link provided below.
https://edge.media-server.com/mmc/p/ukc9sp9j/lan/en/
It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.”. Please follow the steps to enter your registration details, then click “Submit.”. Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials.
Starting 10 minutes before the conference call begins, you will be able to view the earnings presentation materials on the site. The materials will also be available for download.
A replay of the conference call will be accessible until August 13, 2026.
Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.
For more information, visit https://sbc-holdings.com/
Use of Non-GAAP Financial Measures
The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.
The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.
The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.
For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
Second Quarter 2025 Financial Results
Total revenues were $43 million, a decrease of 18% year-over-year, primarily due to a revised fee structure for franchising services implemented starting from April 2025, the discontinuation staffing services business, and divestiture of SNA and Kijimadaira, partially offset by growth in procurement, rental services, and other revenue streams.
Net income attributable to SBC Medical Group for the three months ended June 30, 2025 was $2.5 million, compared to $18.5 million in the same period of 2024. The decrease was largely attributed to unfavorable changes in other income and expenses, primarily due to higher foreign exchange losses.
EBITDA1 was $15 million, a decrease of 46% year-over-year, primarily due to lower revenue following the termination of the staffing services business, the deconsolidation of SNA and Kijimadaira, and revision of fee structure.
Conference Call
The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live.
Please register in advance of the conference using the link provided below.
https://edge.media-server.com/mmc/p/ukc9sp9j/lan/en/
It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.”. Please follow the steps to enter your registration details, then click “Submit.”. Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials.
Starting 10 minutes before the conference call begins, you will be able to view the earnings presentation materials on the site. The materials will also be available for download.
A replay of the conference call will be accessible until August 13, 2026.
Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchise clinics.
For more information, visit https://sbc-holdings.com/
Use of Non-GAAP Financial Measures
The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company’s results of operations, enhance the overall understanding of the Company’s past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.
The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company’s operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP.
The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.
For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.”
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
| 1 EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section “Use of Non-GAAP Financial Measures” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results.” |
| 2 The figures take into accounts of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC |
| 3 The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, AHH Clinic but does not take account of customers of JUN CLINIC, but excluding free counseling. The applicable periods are from July 1, 2024, to June 30, 2025 |
| 4 The figures include franchising of SBC brand clinics, Rize Clinic, and Gorilla Clinic, but does not take account of customers of AHH clinics and JUN CLINIC excluding free counseling. The percentage of customers who visited our franchisee’s clinics twice or more. |
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE SHEETS
| June 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 152,740,882 | $ | 125,044,092 | ||||
| Accounts receivable | 2,350,368 | 1,413,433 | ||||||
| Accounts receivable – related parties | 48,920,843 | 28,846,680 | ||||||
| Inventories | 1,705,237 | 1,494,891 | ||||||
| Finance lease receivables, current – related parties | 9,128,931 | 5,992,585 | ||||||
| Customer loans receivable, current | 10,552,623 | 10,382,537 | ||||||
| Prepaid expenses and other current assets | 14,051,746 | 11,276,802 | ||||||
| Other receivables – related parties | 1,891,408 | — | ||||||
| Total current assets | 241,342,038 | 184,451,020 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 8,058,016 | 8,771,902 | ||||||
| Intangible assets, net | 1,584,543 | 1,590,052 | ||||||
| Long-term investments, net | 3,593,087 | 3,049,972 | ||||||
| Goodwill, net | 5,011,511 | 4,613,784 | ||||||
| Cryptocurrencies | 535,882 | — | ||||||
| Finance lease receivables, non-current – related parties | 13,197,979 | 8,397,582 | ||||||
| Operating lease right-of-use assets | 4,583,393 | 5,267,056 | ||||||
| Finance lease right-of-use assets | 516,932 | — | ||||||
| Deferred tax assets | 2,343,302 | 9,798,071 | ||||||
| Customer loans receivable, non-current | 5,934,636 | 5,023,551 | ||||||
| Long-term prepayments | 1,755,292 | 1,745,801 | ||||||
| Long-term investments in MCs – related parties | 19,381,422 | 17,820,910 | ||||||
| Other assets | 7,461,224 | 15,553,453 | ||||||
| Total non-current assets | 73,957,219 | 81,632,134 | ||||||
| Total assets | $ | 315,299,257 | $ | 266,083,154 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 16,290,206 | $ | 13,875,179 | ||||
| Accounts payable – related parties | 3,245,989 | 659,044 | ||||||
| Current portion of long-term loans | 69,420 | 96,824 | ||||||
| Notes and other payables, current – related parties | 3,272,048 | 26,255 | ||||||
| Advances from customers | 512,123 | 820,898 | ||||||
| Advances from customers – related parties | 10,333,007 | 11,739,533 | ||||||
| Income tax payable | 14,133,163 | 18,705,851 | ||||||
| Operating lease liabilities, current | 3,623,871 | 4,341,522 | ||||||
| Finance lease liabilities, current | 161,340 | — | ||||||
| Accrued liabilities and other current liabilities | 6,229,797 | 8,103,194 | ||||||
| Due to related party | 2,810,647 | 2,823,590 | ||||||
| Total current liabilities | 60,681,611 | 61,191,890 | ||||||
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued)
| June 30, 2025 | December 31, 2024 | |||||||
| Non-current liabilities: | ||||||||
| Long-term loans | 7,031,506 | 6,502,682 | ||||||
| Notes and other payables, non-current – related parties | — | 5,334 | ||||||
| Deferred tax liabilities | 353,517 | 926,023 | ||||||
| Operating lease liabilities, non-current | 1,208,516 | 1,241,526 | ||||||
| Finance lease liabilities, non-current | 164,721 | — | ||||||
| Other liabilities | 1,206,815 | 1,193,541 | ||||||
| Total non-current liabilities | 9,965,075 | 9,869,106 | ||||||
| Total liabilities | 70,646,686 | 71,060,996 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024) | — | — | ||||||
| Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 103,098,442 and 102,750,816 shares outstanding as of June 30, 2025 and December 31, 2024, respectively) | 10,388 | 10,302 | ||||||
| Additional paid-in capital | 72,196,114 | 62,513,923 | ||||||
| Treasury stock (at cost, 782,809 and 270,000 shares as of June 30, 2025 and December 31, 2024, respectively) | (5,115,262 | ) | (2,700,000 | ) | ||||
| Retained earnings | 213,423,693 | 189,463,007 | ||||||
| Accumulated other comprehensive loss | (35,922,942 | ) | (54,178,075 | ) | ||||
| Total SBC Medical Group Holdings Incorporated stockholders’ equity | 244,591,991 | 195,109,157 | ||||||
| Non-controlling interests | 60,580 | (86,999 | ) | |||||
| Total stockholders’ equity | 244,652,571 | 195,022,158 | ||||||
| Total liabilities and stockholders’ equity | $ | 315,299,257 | $ | 266,083,154 | ||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues, net – related parties | $ | 38,944,898 | $ | 51,039,038 | $ | 84,202,043 | $ | 101,509,245 | ||||||||
| Revenues, net | 4,413,949 | 2,063,042 | 6,485,505 | 6,400,877 | ||||||||||||
| Total revenues, net | 43,358,847 | 53,102,080 | 90,687,548 | 107,910,122 | ||||||||||||
| Cost of revenues (including cost of revenues from related parties of $4,669,602 and $3,616,103 for the three months ended June 30, 2025 and 2024, and $8,126,530 and $5,413,462 for the six months ended June 30, 2025 and 2024, respectively) | 13,348,270 | 13,682,405 | 22,943,887 | 28,971,072 | ||||||||||||
| Gross profit | 30,010,577 | 39,419,675 | 67,743,661 | 78,939,050 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $415,767 and nil for the three months ended June 30, 2025 and 2024, and $415,767 and nil for the six months ended June 30, 2025 and 2024, respectively) | 15,456,385 | 12,129,115 | 28,987,395 | 27,187,605 | ||||||||||||
| Total operating expenses | 15,456,385 | 12,129,115 | 28,987,395 | 27,187,605 | ||||||||||||
| Income from operations | 14,554,192 | 27,290,560 | 38,756,266 | 51,751,445 | ||||||||||||
| Other income (expenses): | ||||||||||||||||
| Interest income | 22,882 | 11,644 | 78,215 | 29,333 | ||||||||||||
| Interest expense | (49,651 | ) | (7,424 | ) | (55,858 | ) | (10,432 | ) | ||||||||
| Other income | 33,771 | 306,291 | 185,099 | 655,972 | ||||||||||||
| Other expenses | (1,132,465 | ) | (514,636 | ) | (2,829,724 | ) | (1,951,292 | ) | ||||||||
| Gain on redemption of life insurance policies | — | — | 8,746,138 | — | ||||||||||||
| Change in fair value of cryptocurrencies | 111,632 | — | 111,632 | — | ||||||||||||
| Gain on disposal of subsidiary | — | — | — | 3,813,609 | ||||||||||||
| Total other income (expenses) | (1,013,831 | ) | (204,125 | ) | 6,235,502 | 2,537,190 | ||||||||||
| Income before income taxes | 13,540,361 | 27,086,435 | 44,991,768 | 54,288,635 | ||||||||||||
| Income tax expense | 11,100,509 | 8,529,110 | 21,059,966 | 16,981,094 | ||||||||||||
| Net income | 2,439,852 | 18,557,325 | 23,931,802 | 37,307,541 | ||||||||||||
| Less: net income (loss) attributable to non-controlling interests | (18,388 | ) | 72,917 | (28,884 | ) | 65,381 | ||||||||||
| Net income attributable to SBC Medical Group Holdings Incorporated | $ | 2,458,240 | $ | 18,484,408 | $ | 23,960,686 | $ | 37,242,160 | ||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustment | $ | 8,623,269 | $ | (9,046,549 | ) | $ | 18,431,596 | $ | (19,240,401 | ) | ||||||
| Total comprehensive income | 11,063,121 | 9,510,776 | 42,363,398 | 18,067,140 | ||||||||||||
| Less: comprehensive income (loss) attributable to non-controlling interests | 184,411 | 22,000 | 147,579 | (70,000 | ) | |||||||||||
| Comprehensive income attributable to SBC Medical Group Holdings Incorporated | $ | 10,878,710 | $ | 9,488,776 | $ | 42,215,819 | $ | 18,137,140 | ||||||||
| Net income per share attributable to SBC Medical Group Holdings Incorporated* | ||||||||||||||||
| Basic and diluted | $ | 0.02 | $ | 0.20 | $ | 0.23 | $ | 0.40 | ||||||||
| Weighted average shares outstanding* | ||||||||||||||||
| Basic and diluted | 103,507,249 | 94,192,433 | 103,392,580 | 94,192,433 | ||||||||||||
| * | Retrospectively restated for effect of reverse recapitalization on September 17, 2024. |
The accompanying notes are an integral part of these unaudited consolidated financial statements.
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net income | $ | 23,931,802 | $ | 37,307,541 | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization expense | 1,264,405 | 1,849,422 | ||||||
| Non-cash lease expense | 2,185,744 | 1,923,890 | ||||||
| Provision for credit losses | 283,752 | 62,804 | ||||||
| Fair value change of long-term investments | 384,523 | 1,045,557 | ||||||
| Gain on disposal of subsidiary | — | (3,813,609 | ) | |||||
| Gain on redemption of life insurance policies | (8,746,138 | ) | — | |||||
| Gain on disposal of property and equipment | (10,804 | ) | (902 | ) | ||||
| Change in fair value of cryptocurrencies | (111,632 | ) | — | |||||
| Deferred income taxes | 7,452,983 | (3,322,728 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (789,577 | ) | (1,423,412 | ) | ||||
| Accounts receivable – related parties | (17,039,113 | ) | 5,843,499 | |||||
| Inventories | (717,972 | ) | 561,921 | |||||
| Finance lease receivables – related parties | (6,482,967 | ) | (1,759,556 | ) | ||||
| Customer loans receivable | 8,081,703 | 7,521,267 | ||||||
| Prepaid expenses and other current assets | (1,349,225 | ) | (1,488,347 | ) | ||||
| Long-term prepayments | 211,988 | (41,412 | ) | |||||
| Other assets | 85,907 | (1,007,431 | ) | |||||
| Accounts payable | 1,165,217 | (8,960,556 | ) | |||||
| Accounts payable – related parties | 2,455,865 | — | ||||||
| Notes and other payables – related parties | (5,031,570 | ) | (5,101,368 | ) | ||||
| Advances from customers | (369,616 | ) | (755,977 | ) | ||||
| Advances from customers – related parties | (2,363,891 | ) | (4,663,233 | ) | ||||
| Income tax payable | (6,030,526 | ) | 5,462,133 | |||||
| Operating lease liabilities | (2,275,398 | ) | (1,998,196 | ) | ||||
| Accrued liabilities and other current liabilities | (2,508,035 | ) | (4,444,172 | ) | ||||
| Other liabilities | (88,593 | ) | 77,625 | |||||
| NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | (6,411,168 | ) | 22,874,760 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | (560,431 | ) | (1,565,333 | ) | ||||
| Purchase of convertible note | — | (1,700,000 | ) | |||||
| Prepayments for property and equipment | (705,351 | ) | — | |||||
| Advances to related parties | — | (617,804 | ) | |||||
| Payments made on behalf of related parties | (1,836,541 | ) | (5,245,990 | ) | ||||
| Purchase of long-term investments | (652,555 | ) | — | |||||
| Purchase of cryptocurrencies | (424,250 | ) | — | |||||
| Long-term loans to others | (13,134 | ) | (62,489 | ) | ||||
| Repayments from related parties | 70,000 | 555,000 | ||||||
| Repayments from others | 56,307 | 44,748 | ||||||
| Proceeds from redemption of life insurance policies | 17,735,717 | — | ||||||
| Disposal of subsidiary, net of cash disposed of | — | (815,819 | ) | |||||
| Proceeds from disposal of property and equipment | 1,728,236 | 1,971 | ||||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 15,397,998 | (9,405,716 | ) | |||||
SBC MEDICAL GROUP HOLDINGS INCORPORATED
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)
| For the Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Borrowings from related parties | 15,000 | — | ||||||
| Repayments of long-term loans | (74,256 | ) | (59,217 | ) | ||||
| Repayments of finance lease liabilities | (278,097 | ) | — | |||||
| Repayments to related parties | (27,943 | ) | (50,124 | ) | ||||
| Repurchase of common stock | (2,415,262 | ) | — | |||||
| Deemed contribution in connection with price modification on disposal of property and equipment | 9,682,277 | — | ||||||
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | 6,901,719 | (109,341 | ) | |||||
| Effect of exchange rate changes | 11,808,241 | (12,679,865 | ) | |||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 27,696,790 | 679,838 | ||||||
| CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD | 125,044,092 | 103,022,932 | ||||||
| CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD | $ | 152,740,882 | $ | 103,702,770 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||
| Cash paid for interest expense | $ | 55,858 | $ | 10,432 | ||||
| Cash paid for income taxes, net | $ | 19,637,454 | $ | 16,191,178 | ||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Property and equipment transferred from long-term prepayments | $ | 246,188 | $ | — | ||||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $ | 104,437 | $ | — | ||||
| Finance lease right-of-use assets obtained in exchange for finance lease liabilities | $ | 612,466 | $ | — | ||||
| Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications | $ | 1,160,680 | $ | 1,376,034 | ||||
| Payables to related parties in connection with loan services provided | $ | 8,175,342 | $ | 16,085,387 | ||||
| Issuance of common stock as incentive shares | $ | 86 | $ | — | ||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
SBC MEDICAL GROUP HOLDINGS INCORPORATED
Unaudited Reconciliations of GAAP and Non-GAAP Results
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
SBC MEDICAL GROUP HOLDINGS INCORPORATED
Unaudited Reconciliations of GAAP and Non-GAAP Results
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Total revenues, net | $ | 43,358,847 | $ | 53,102,080 | $ | 90,687,548 | 107,910,122 | |||||||||
| Income from operations | 14,554,192 | 27,290,560 | 38,756,266 | 51,751,445 | ||||||||||||
| Depreciation and amortization expense | 636,101 | 830,945 | 1,264,405 | 1,849,422 | ||||||||||||
| EBITDA | 15,190,293 | 28,121,505 | 40,020,671 | 53,600,867 | ||||||||||||
| EBITDA margin | 35 | % | 53 | % | 44 | % | 50 | % | ||||||||
The accompanying notes are an integral part of these unaudited consolidated financial statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813939975/en/
Contact
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
Source : SBC Medical Group Holdings Incorporated
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813939975/en/
Contact
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
Source : SBC Medical Group Holdings Incorporated
Subscribe to:
Posts (Atom)